Maximus (NYSE:MMS) Issues Earnings Results

Maximus (NYSE:MMS) posted its earnings results on Thursday. The health services provider reported $1.62 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.01), Zacks reports. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.34 billion. Maximus had a net margin of 5.83% and a return on equity of 24.44%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.46 EPS. Maximus updated its FY 2026 guidance to 7.950-8.250 EPS.

Maximus Trading Up 7.3%

NYSE MMS opened at $83.45 on Thursday. The company has a quick ratio of 2.27, a current ratio of 2.27 and a debt-to-equity ratio of 0.91. The stock’s 50-day simple moving average is $86.11 and its two-hundred day simple moving average is $79.33. Maximus has a twelve month low of $63.77 and a twelve month high of $92.50. The company has a market capitalization of $4.70 billion, a price-to-earnings ratio of 15.32 and a beta of 0.57.

Maximus Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.30 per share. The ex-dividend date is Friday, November 14th. This represents a $1.20 annualized dividend and a yield of 1.4%. Maximus’s payout ratio is presently 22.10%.

Analyst Upgrades and Downgrades

MMS has been the subject of several recent analyst reports. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 27th. Weiss Ratings raised shares of Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.00.

Insider Buying and Selling at Maximus

In related news, insider Michelle F. Link sold 1,610 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total value of $146,284.60. Following the completion of the sale, the insider owned 13,508 shares in the company, valued at $1,227,336.88. The trade was a 10.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Maximus

Several institutional investors and hedge funds have recently made changes to their positions in MMS. Advisory Services Network LLC purchased a new stake in Maximus during the third quarter valued at about $32,000. Canada Pension Plan Investment Board purchased a new position in Maximus in the 2nd quarter worth approximately $35,000. Danske Bank A S bought a new stake in Maximus in the third quarter valued at approximately $55,000. National Bank of Canada FI grew its holdings in shares of Maximus by 38.9% in the third quarter. National Bank of Canada FI now owns 1,118 shares of the health services provider’s stock worth $102,000 after purchasing an additional 313 shares during the last quarter. Finally, Wexford Capital LP purchased a new position in shares of Maximus in the third quarter worth $114,000. Institutional investors own 97.21% of the company’s stock.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.